Title

Clearing The Amyloid In Alzheimer's: Progress Towards Earlier Diagnosis And Effective Treatments – An Update For Clinicians

Document Type

Article

Publisher

Future Science Group

Faculty

Faculty of Health, Engineering and Science

School

School of Medical Sciences, Centre of Excellence for Alzheimer's Disease Research & Care

RAS ID

19679

Comments

Asih, P. R., Chatterjee, P., Verdile, G., Gupta, V. B., Trengove, R. D., & Martins, R. N. (2014). Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments-an update for clinicians. Neurodegenerative disease management, 4(5), 363-378.Original article available here

Abstract

A beta (Aβ or β-amyloid) is a key molecule in Alzheimer's disease (AD) pathogenesis. According to the ‘amyloid hypothesis’, the gradual accumulation of Aβ triggers events which results in neuronal loss in regions of the brain involved with memory and learning. Diverse agents have been developed to reduce brain Aβ accumulation or to enhance its clearance. Some have progressed to human trials, however all have failed to improve cognition in patients. This has led researchers to question whether Aβ is really the problem. However, the trials have been targeting end stages of AD, by which stage extensive irreversible neuronal damage has already occurred. Intervention is required preclinically, therefore preclinical AD biomarkers are needed. In this regard, amyloid imaging and cerebrospinal fluid biomarkers are leading the way, with plasma biomarkers and eye tests also being investigated. This review covers the current state of knowledge of Aβ as an early diagnostic biomarker and as a therapeutic target in AD.

DOI

10.2217/nmt.14.29

Share

 
COinS